Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC
NCT ID: NCT03243916
Last Updated: 2017-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2017-08-15
2020-07-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
NCT01318200
On the Cyberknife Dose Fraction of Liver Cancer Treatment
NCT03295500
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
NCT04512833
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
NCT01833299
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
NCT03575806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
combination
TACE plus cyber knife
TACE plus Cyber knife
Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TACE plus Cyber knife
Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No lymph node metastasis or distant metastasis
* Tumor diameter at least 10 cm
* Hepatic lesions are not suitable for surgical resection or the patient refuse to surgical treatment
* Eastern Clinical Oncology Group (ECOG)score is 0， 1or2
* No history of abdominal radiotherapy
* Inoperable and untransplantable,Child-pugh score A or B
* Normal liver volume exceeds 700 cm3
Exclusion Criteria
* The maximum diameter of tumor is less than 10cm;
* The liver Child is graded C;
* Contraindication for radiotherapy;
* Active gastrointestinal bleeding occurred within 2 weeks before enrollment
* Pregnancy
* Undergoing chemotherapy throughout the past six months
* Diffuse hepatocellular carcinoma
* Main portal vein tumor embolization
* Undergoing other simultaneous treatment
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
YuLi
Vice Director of Department of Radiotherappy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yu Li, MD
Role: PRINCIPAL_INVESTIGATOR
China PLA hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA Gereral Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yu Li, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChinaPLAGH-MHCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.